Lanean...

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies

Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4, anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while these therapies are very efficient in certain tumors, they remain poorly efficient in others. This might be explained by...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:F1000Res
Egile Nagusiak: Gorvel, Laurent, Olive, Daniel
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: F1000 Research Limited 2020
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7222031/
https://ncbi.nlm.nih.gov/pubmed/32489646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.22877.1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!